MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of
available-for-sale investment...
$17,500K
Net cash provided by
(used in) investing...
$11,494K
Canceled cashflow
$6,006K
Net change in cash,
cash equivalents and...
-$1,165K
Canceled cashflow
$11,494K
Stock-based compensation
$1,307K
Other receivables
-$396K
Amortization of right-of-use
assets
$232K
Depreciation and
amortization
$162K
Prepaid expenses and
other assets
-$91K
Purchases of
available-for-sale investment...
$5,868K
Purchases of property and
equipment
$138K
Net cash used in
operating activities
-$12,517K
Canceled cashflow
$2,188K
Net cash (used in)
provided by financing...
-$142K
total other income
(expense), net
$644K
Consolidated net loss
-$10,792K
Accounts payable and
accrued expenses
-$3,467K
Canceled cashflow
$644K
Accretion of discount of
available-for-sale investment...
$255K
Operating lease liability
-$191K
Principal paid on finance
lease liabilities
$142K
Total research and
development expenses
$7,317K
Total general and
administrative expenses
$4,119K
Back
Back
Cash Flow
source: myfinsight.com
aTYR PHARMA INC (ATYR)
aTYR PHARMA INC (ATYR)